oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events
Örebro universitet, Institutionen för hälsovetenskap och medicin. Department of Cardiology, Örebro University Hospital, Örebro, Sweden.
Örebro universitet, Institutionen för hälsovetenskap och medicin. Department of Cardiology, Örebro University Hospital, Örebro, Sweden.
Örebro universitet, Institutionen för hälsovetenskaper. Department of Cardiology, Örebro University Hospital, Örebro, Sweden.ORCID-id: 0000-0002-2654-9427
Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Vise andre og tillknytning
2011 (engelsk)Inngår i: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 270, nr 3, s. 281-290Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective:To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) andproarrhythmic events.

Design: Retrospective,observational cohort study.Setting.Single-centre study at Örebro University Hospital, Sweden.

Setting: Single-centre study at Orebro University Hospital, Sweden.

Subjects: A total of 112 patients with paroxysmal (51%) or persistent (49%) AF (mean age 60 ± 11 years) were included after identifying all patients with AF who initiated oral flecainide treatment (mean dose 203 ± 43 mg per day) between 1998 and 2006. Standard exclusion⁄inclusion criteria for flecainide were used,andflecainidetreatmentwasusually combined withanatrioventricular-blocking agent (89%).

Main outcome measure: Death was classified as sudden or nonsudden according to standard definitions. Proarrhythmia was defined as cardiac syncope or lifethreatening arrhythmia.

Results: Eight deaths were reported during a mean follow- up of 3.4 ± .4 years. Compared to the general population, the standardized mortality ratios were 1.57 (95% confidence interval (CI) 0.68–3.09) for allcause mortality and 4.16 (95% CI 1.53–9.06) for death from cardiovascular disease. Three deaths were classified as SCDs. Proarrhythmic events occurred in six patients (two each with wide QRS tachycardia, 1 : 1 conducted atrial flutter and syncope during exercise).

Conclusion: We found an increased incidence of SCD or proarrhythmic events in this real-world study of flecainide used for the treatment of AF. The findings suggest that further investigation into the safety of flecainide for the treatment of patients with AF is warranted.

sted, utgiver, år, opplag, sider
John Wiley & Sons, 2011. Vol. 270, nr 3, s. 281-290
Emneord [en]
atrial fibrillation, flecainide, proarrhythmia, safety, sudden cardiac death
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-22942DOI: 10.1111/j.1365-2796.2011.02395.xISI: 000293793600011PubMedID: 21635583Scopus ID: 2-s2.0-80051576394OAI: oai:DiVA.org:oru-22942DiVA, id: diva2:527994
Merknad

Funding Agencies:

Boehringer-Ingelheim  

Sanofi-Aventis  

Astra Zeneca  

Bristol-Myers Squibb 

Tilgjengelig fra: 2012-05-23 Laget: 2012-05-23 Sist oppdatert: 2018-09-11bibliografisk kontrollert
Inngår i avhandling
1. Atrial fibrillation: inflammatory and pharmacological studies
Åpne denne publikasjonen i ny fane eller vindu >>Atrial fibrillation: inflammatory and pharmacological studies
2012 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
sted, utgiver, år, opplag, sider
Örebro: Örebro universitet, 2012. s. 75
Serie
Örebro Studies in Medicine, ISSN 1652-4063 ; 70
Emneord
Atrial fibrillation, inflammation, randomised, sudden cardiac
HSV kategori
Forskningsprogram
Medicin
Identifikatorer
urn:nbn:se:oru:diva-22590 (URN)978-91-7668-875-5 (ISBN)
Disputas
2012-06-15, Wilandersalen, Universitetssjukhuset, Örebro, 09:00 (svensk)
Opponent
Veileder
Tilgjengelig fra: 2012-04-19 Laget: 2012-04-19 Sist oppdatert: 2017-10-17bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Almroth, HenrikAndersson, TorbjornFengsrud, Espen

Søk i DiVA

Av forfatter/redaktør
Almroth, HenrikAndersson, TorbjornFengsrud, Espen
Av organisasjonen
I samme tidsskrift
Journal of Internal Medicine

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 418 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf